Tamara Tchkonia

Jul 2, 2024 | nature.com | Joshua N Farr |Jad G. Sfeir |Dominik Saul |Kai Yu |Tamara Tchkonia |Nathan K. LeBrasseur | +2 more

AbstractPreclinical evidence demonstrates that senescent cells accumulate with aging and that senolytics delay multiple age-related morbidities, including bone loss. Thus, we conducted a phase 2 randomized controlled trial of intermittent administration of the senolytic combination dasatinib plus quercetin (D + Q) in postmenopausal women (n = 60 participants).

Apr 22, 2024 | agsjournals.onlinelibrary.wiley.com | Tamara Tchkonia |Stephen B Kritchevsky |George A. Kuchel |James Kirkland

Aging processes are the leading risk factor for most serious diseases and disabilities across the lifespan including dementias, cancers, atherosclerosis, and frailty as well as impaired physical resilience to such stresses as infections, or surgery.1-3 Conditions related to fundamental aging mechanisms are the major drivers of morbidity, mortality, and health costs but have proven difficult to control.

Sep 7, 2023 | nature.com | Juan Pablo Palavicini |Habil Zare |Peng Xu |Ronald Petersen |Tamara Tchkonia |James Kirkland | +3 more

Prince, M. J. et al. World Alzheimer Report 2015—The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends (Alzheimer’s Disease International, 2015). Cummings, J., Ritter, A. & Zhong, K. Clinical trials for disease-modifying therapies in Alzheimer’s disease: a primer, lessons learned, and a blueprint for the future. J. Alzheimers Dis. 64, S3–S22 (2018). Article  PubMed  PubMed Central  Google Scholar  Aisen, P. S. et al. The future of anti-amyloid trials. J. Prev. Alzheimers Dis.